Vous êtes ici


Potential role of allopregnanolone for a safe and effective therapy of neuropathic pain.

Patte-Mensah C, Meyer L, Taleb O, Mensah-Nyagan AG. Prog Neurobiol. 2014 Feb;113:70-8.

This paper shows that the neurosteroid allopregnanolone, which possesses a high therapeutic potential and a good toxicological profile, may be used to develop effective and safe strategies against chronic neuropathic pain.


Serum analysis by 1H nuclear magnetic resonance spectroscopy: a new tool for distinguishing neuromyelitis optica from multiple sclerosis.

Moussallieh FM, Elbayed K, Chanson JB, Rudolf G, Piotto M, De Seze J, Namer IJ. Mult Scler. 2014 Apr;20(5):558-65.

This study demonstrates that several metabolites may play an important role in the differential diagnosis between MS and NMO. A patent has been obtained for these potential targets.


MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.

Fox RJ, Cree BA, De Sèze J, Gold R, Hartung HP, Jeffery D, Kappos L, Kaufman M, Montalbán X, Weinstock-Guttman B, Anderson B, Natarajan A, Ticho B, Duda P. Neurology. 2014 Apr 29;82(17):1491-8.

This study provides Class II evidence that for patients with MS taking natalizumab who are relapse-free for 1 year, stopping natalizumab increases the risk of MS relapse or MRI disease activity as compared with continuing natalizumab.


Long-term follow-up of a randomized trial on 118 patients with polyarteritis nodosa or microscopic polyangiitis without poor-prognosis factors.

Samson M, Puéchal X, Devilliers H, Ribi C, Cohen P, Bienvenu B, Ruivard M, Terrier B, Pagnoux C, Mouthon L, Guillevin L; French Vasculitis Study Group (FVSG). Autoimmun Rev. 2014 Feb;13(2):197-205.

The purpose of this study was to assess the long-term outcomes of patients with polyarteritis nodosa (PAN) or microscopic polyangiitis (MPA) without Five-Factor Score (FFS)-defined poor-prognosis factors (FFS=0) and enrolled in a prospective clinical trial.


Thiopalmitoylation of altered peptide ligands enhances their protective effects in an animal model of multiple sclerosis.

Cloake NC, Beaino W, Trifilieff E, Greer JM. J Immunol. 2014 Mar 1;192(5):2244-51.

These results show that thiopalmitoylation of MHC class II-restricted peptides is a simple way to enhance their effects in vivo and could have wide therapeutic application.


Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients.

Michel L, Vukusic S, De Seze J, Ducray F, Ongagna JC, Lefrère F, Jacq-Foucher M, Confavreux C, Wiertlewski S, Laplaud DA. J Neurol Neurosurg Psychiatry. 2014 Mar;85(3):279-83.

The results suggest that MMF can improve or stabilise MS patients and can be used as an alternative therapy.


Improvement of neuronal bioenergetics by neurosteroids: implications for age-related neurodegenerative disorders.

Grimm A, Schmitt K, Lang UE, Mensah-Nyagan AG, Eckert A.Biochim Biophys Acta. 2014 Dec;1842(12 Pt A):2427-38.

Our results indicate that the ability to boost mitochondria is not unique to estradiol, but seems to be a rather common mechanism of different steroids in the brain. Thus, neurosteroids may act upon neuronal bioenergetics in a delicate balance and an age-related steroid disturbance might be involved in mitochondrial dysfunction underlying neurodegenerative disorders.


Lyme neuroborreliosis and dementia.

Blanc F, Philippi N, Cretin B, Kleitz C, Berly L, Jung B, Kremer S, Namer IJ, Sellal F, Jaulhac B, de Seze J. J Alzheimers Dis. 2014;41(4):1087-93.

Pure Lyme dementia exists and has a good outcome after antibiotics. It is advisable to do Lyme serology in demented patients, and if serology is positive, to do CSF analysis with AI. Neurodegenerative dementia associated with positive AI also exists, which may have been revealed by the involvement of Borrelia in the CNS.


Probiotics (VSL#3) prevent endothelial dysfunction in rats with portal hypertension: role of the angiotensin system.

Rashid SK, Khodja NI, Auger C, Alhosin M, Boehm N, Oswald-Mammosser M, Schini-Kerth VB. PLoS One. 2014 May 15;9(5).

These findings indicate that VSL#3 ingestion prevents endothelial dysfunction in the mesenteric artery of CBDL rats, and this effect is associated with an improved vascular oxidative stress most likely by reducing bacterial translocation and the local angiotensin system.


Radiologically isolated syndrome: 5-year risk for an initial clinical event.

Okuda DT, Siva A, Kantarci O, Inglese M, Katz I, Tutuncu M, Keegan BM, Donlon S, Hua le H, Vidal-Jordana A, Montalban X, Rovira A, Tintoré M, Amato MP, Brochet B, de Seze J, Brassat D, Vermersch P, De Stefano N, Sormani MP, Pelletier D, Lebrun C; Radiologically Isolated Syndrome Consortium (RISC); Club Francophone de la Sclérose en Plaques (CFSEP). PLoS One. 2014 Mar 5;9(3).

These data provide supportive evidence that a meaningful number of RIS subjects evolve to a first clinical symptom. An age <37 y, male sex, and spinal cord involvement appear to be the most important independent predictors of symptom onset.


Isolated anti-β2-glycoprotein I antibodies in neurology: a frontier syndrome between multiple sclerosis and antiphospholipid syndrome?

Renaud M, Aupy J, Uring-Lambert B, Chanson JB, Collongues N, Blanc F, De Sèze J. Eur J Neurol. 2014 Jun;21(6):901-6.

The anti-β2-GPI antibody seems to be involved in two types of neurological disease: vascular or inflammatory 'multiple sclerosis-like' disease. These two types of patients frequently develop an autoimmune disease (multiple sclerosis, systemic lupus erythematosus, APS). However, a large proportion of the patients had an undefined profile with aspecific cerebral lesions and required monitoring. This study raises questions about a separate entity at the border between APS and multiple sclerosis which remains to be better defined in a larger cohort.


A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort.

Outteryck O, Ongagna JC, Brochet B, Rumbach L, Lebrun-Frenay C, Debouverie M, Zéphir H, Ouallet JC, Berger E, Cohen M, Pittion S, Laplaud D, Wiertlewski S, Cabre P, Pelletier J, Rico A, Defer G, Derache N, Camu W, Thouvenot E, Moreau T, Fromont A, Tourbah A, Labauge P, Castelnovo G, Clavelou P, Casez O, Hautecoeur P, Papeix C, Lubetzki C, Fontaine B, Couturier N, Bohossian N, Clanet M, Vermersch P, de Sèze J, Brassat D; BIONAT Network,; CFSEP. Eur J Neurol. 2014;21(1):40-8.

The efficacy of NTZ therapy on relapsing-remitting MS in a real life setting is confirmed in the BIONAT cohort. The next step will be the identification of biomarkers predicting response to NTZ therapy and adverse events.


Gamma-hydroxybutyrate, acting through an anti-apoptotic mechanism, protects native and amyloid-precursor-protein-transfected neuroblastoma cells against oxidative stress-induced death.

Wendt G, Kemmel V, Patte-Mensah C, Uring-Lambert B, Eckert A, Schmitt MJ, Mensah-Nyagan AG. Neuroscience. 2014 Mar 28;263:203-15.

These results, providing multi-parametric evidence for the existence of neuroprotective action of GHB, also open interesting perspectives for the development of GHB analog-based strategies against neurodegeneration or nerve cell death.


A case of recurrent facial pain associated with a Pourfour du Petit syndrome: a new entity?

Collongues N, Labouret P, Speeg C, de Seze J.

Headache. 2014 Feb;54(2):373-7.

We report the case of a 38-year-old woman with a history of migraine who experienced an association of recurrent unilateral facial pain and Pourfour du Petit syndrome. This new entity raises the question of a novel autonomic dysfunction in short-lasting unilateral neuralgiform headaches with cranial autonomic symptoms or an unexpected presentation of migraine.


Chronic Bickerstaff's encephalitis with cognitive impairment, a reality?

Renaud M, Aupy J, Camuset G, Collongues N, Chanson JB, de Seze J, Blanc F. BMC Neurol. 2014 May 6;14:99.

This case raises the question of the existence of a chronic form of BE with cognitive impairment, in the same way as chronic inflammatory demyelinating polyneuropathy is considered to be a chronic form of Guillain-Barré syndrome.


The small GTPase RhoA regulates the expression and function of the sodium channel Nav1.5 in breast cancer cells.

Dulong C, Fang YJ, Gest C, Zhou MH, Patte-Mensah C, Mensah-Nyagan AG, Vannier JP, Lu H, Soria C, Cazin L, Mei YA, Varin R, Li H. Int J Oncol. 2014 Feb;44(2):539-47.

Altogether, these findings revealed: i) the key role of the small GTPase RhoA in upregulation of Nav1.5 channel expression and tumor aggressiveness, and ii) the existence of a positive feedback of Nav1.5 channels on RhoA protein levels.


Impaired mental simulation of specific past and future personal events in non-depressed multiple sclerosis patients.

Ernst A, Blanc F, de Seze J, Sellal F, Chauvin B, Manning L. J Neurol Sci. 2014 Oct 15;345(1-2):68-74.

The results showed, for the first time, the co-occurrence of deficit of remembering the past and imagining the future in MS patients. They also showed more difficulty in imagining future events than remembering past events for both patients and normal controls. MS being a neurological condition very frequent in the young adult population, the clinical considerations of our study might be of interest. Indeed, they give rise to new insights on MS patients' daily life difficulties related to impaired mental simulation of personal events despite general abilities, including anterograde memory, only mildly or not impaired.


Immunological profiles determine neurological involvement in Sjögren's syndrome.

Jamilloux Y, Magy L, Hurtevent JF, Gondran G, de Seze J, Launay D, Ly KH, Lambert M, Hachulla E, Hatron PY, Vidal E, Fauchais AL. Eur J Intern Med. 2014 Feb;25(2):177-81.

In pSS, patients with sensorimotor neuropathies and pure sensory neuropathies have distinct extraglandular and immunological profiles.


Improvement of neuronal bioenergetics by neurosteroids: implications for age-related neurodegenerative disorders.

Grimm A, Schmitt K, Lang UE, Mensah-Nyagan AG, Eckert A.

Biochim Biophys Acta. 2014 Dec;1842(12 Pt A):2427-38